Granulocyte Macrophage Colony Stimulating Factor Companies

ID: MRFR/Pharma/4951-HCR

100 Pages

Rahul Gotadki

September 2025

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is a naturally occurring protein in the body that stimulates the production and function of white blood cells, including granulocytes and macrophages. GM-CSF is used therapeutically in medicine to boost the immune system, particularly in individuals undergoing certain medical treatments. Companies involved in GM-CSF development and manufacturing play a crucial role in providing therapeutic solutions.

Granulocyte-Macrophage Colony-Stimulating Factor Market Research Report – Forecast to 2032 Infographic

Summary Table of Contents Segmentation Infographic

Top Industry Leaders in the Granulocyte Macrophage Colony Stimulating Factor Market

Granulocyte-Macrophage Colony-Stimulating Factor Key Companies

Latest Granulocyte-Macrophage Colony-Stimulating Factor Companies Update

Chugai Pharmaceutical The leading manufacturer of filgrastim (Granulocyte) announced plans to expand their global production capacity due to increasing demand for the GM-CSF therapy.

Coherus BioSciences Received US FDA approval for Udencya, a biosimilar version of pegfilgrastim, offering a more affordable alternative for managing chemotherapy-induced neutropenia.

Kyowa Hakko Kirin Developed a long-acting GM-CSF variant (NKTR-102) in collaboration with Nektar Therapeutics, demonstrating promising efficacy in clinical trials for neutropenia prevention.

List of Granulocyte-Macrophage Colony-Stimulating Factor Key Companies in the Market

Xconomy Inc.

Partner Therapeutics (PTx)

Sanofi-Aventis U.S. LLC

Novartis AG

Thermo Fisher Scientific

Merck KGaA